Study details
Enrolling now
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Barbara Burtness
NCT IDNCT05317000ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 5.5 years
Ages
18+
Locations
1 site in CT
What this study is about
Researchers are testing whether 5-azacytidine, alone or with nivolumab, can improve the treatment of head and neck cancer caused by HPV. The trial will last for about two years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 5-azacytidine
- 2.Take Combination 5-azacytidine and nivolumab
- 3.Take Nivolumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
azacitidine, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
Drug routes
infusion
Endpoints
Secondary: Occurrence of toxicity
Body systems
Oncology